Home › Neuroblastoma › Wisconsin › Madison
Neuroblastoma clinical trials in Madison, WI
4 studies for Neuroblastoma are looking for participants at sites in and around Madison (within about 30 miles). Open a study to see who can join and how to contact the study team.
Recruiting for a study here? Feature it at the top of this page — $99 for 30 days →
Dinutuximab With Chemotherapy, Surgery and Stem Cell Transplantation for the Treatment of Children With Newly Diagnosed High Risk Neuroblastoma
RecruitingPhase 3
- University of Wisconsin Carbone Cancer Center - University Hospital, Madison
Testing the Addition of 131I-MIBG or Lorlatinib to Intensive Therapy in People With High-Risk Neuroblastoma (NBL)
RecruitingPhase 3
- University of Wisconsin Carbone Cancer Center - University Hospital, Madison
SPEARHEAD-3 Pediatric Study
RecruitingPhase 1/2
- University of Wisconsin Cancer Center, Madison
Alpha/Beta CD19+ Depleted Haploidentical Transplantation + Zometa for Pediatric Hematologic Malignancies and Solid Tumors
RecruitingPhase 1
- University of Wisconsin Carbone Cancer Center, Madison
About Neuroblastoma
Neuroblastoma is a cancer in nerve tissue in the adrenal gland, neck, chest, or spinal cord. It often affects young children. Read about treatments.
More about Neuroblastoma on MedlinePlus
Neuroblastoma trials in other cities
- Boston, MA13 studies
- Washington, DC11 studies
- New York City, NY10 studies
- Memphis, TN9 studies
- Philadelphia, PA9 studies
- Dallas, TX9 studies
- St. Louis, MO9 studies
- Aurora, CO8 studies
- Hartford, CT8 studies
- Minneapolis, MN8 studies
- Birmingham, AL8 studies
- Atlanta, GA7 studies
Other studies in Madison
- Prostate Cancer29 studies
- Colorectal Cancer22 studies
- Breast Cancer22 studies
- Metastatic Cancer21 studies
- Non-Small Cell Lung Cancer16 studies
- Acute Myeloid Leukemia16 studies
- Melanoma15 studies
- Cancer (all types)14 studies
- Ovarian Cancer13 studies
- Stomach Cancer11 studies
- Lung Cancer10 studies
- Pancreatic Cancer10 studies
From ClinicalTrials.gov, data retrieved Oct 5, 2026. Each study sets its own eligibility; the study team decides who can join.